摘要
目的探究特布他林联合糖皮质激素治疗慢性阻塞性肺疾病(慢阻肺)急性加重期的临床疗效。方法120例慢阻肺急性加重期患者,采用随机数字表法分为常规组及实验组,各60例。常规组采用特布他林治疗,实验组采用糖皮质激素联合特布他林治疗。比较两组临床治疗效果、不良反应发生率及治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC]及血气指标[动脉血氧分压(PaO_(2))、动脉二氧化碳分压(PaCO_(2))]水平。结果实验组患者治疗总有效率为93.33%,高于常规组的80.00%,差异有统计学意义(P<0.05)。实验组不良反应发生率为3.34%(2/60),低于常规组的16.67%(10/60),差异有统计学意义(P<0.05)。治疗后,实验组患者FVC、FEV1、FEV1/FVC水平分别为(2.88±0.24)L、(3.28±0.32)L、(84.88±4.56)%,均优于治疗前的(2.21±0.21)L、(1.64±0.42)L、(54.02±6.68)%,常规组患者FVC、FEV1、FEV1/FVC水平分别为(2.36±0.35)L、(2.32±0.46)L、(74.31±6.18)%,均优于治疗前的(2.18±0.25)L、(1.66±0.33)L、(54.18±5.92)%,且实验组FVC、FEV1、FEV1/FVC改善程度优于常规组,差异具有统计学意义(P<0.05)。治疗后,实验组患者PaO_(2)(71.45±4.95)mm Hg(1 mm Hg=0.133 kPa)高于治疗前的(51.02±6.38)mm Hg,PaCO_(2)(45.19±6.18)mm Hg低于治疗前的(68.95±8.52)mm Hg,常规组患者PaO_(2)(64.28±5.15)mm Hg高于治疗前的(51.18±6.12)mm Hg,PaCO_(2)(50.27±5.79)mm Hg低于治疗前的(68.44±8.01)mm Hg,实验组患者PaO_(2)高于常规组,PaCO_(2)低于常规组,差异具有统计学意义(P<0.05)。结论针对慢阻肺急性加重期患者应用特布他林联合糖皮质激素治疗,临床疗效突出,在肺功能及血气指标改善方面具有显著作用,且不良反应较少,临床安全性更高。
Objective To investigate the clinical efficacy of terbutaline combined with glucocorticoid in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 120 patients with acute exacerbation of chronic obstructive pulmonary disease were divided into a conventional group and an experimental group according to random numerical table,with 60 cases in each group.The conventional group was treated with terbutaline,and the experimental group was treated with terbutaline and glucocorticoid.The clinical effect,occurrence of adverse reactions,pulmonary function indicators[forced vital capacity(FVC),forced expiratory volume in the 1st second(FEV1),FEV1/FVC],and blood gas indicators[arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2))]before and after treatment were compared between the two groups.Results The total effective rate of the experimental group was 93.33%,which was higher than 80.00%of the conventional group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the experimental group was 3.34%(2/60),which was lower than 16.67%(10/60)of the conventional group,and the difference was statistically significant(P<0.05).After treatment,the levels of FVC,FEV1 and FEV1/FVC of the experimental group were(2.88±0.24)L,(3.28±0.32)L and(84.88±4.56)%,which were better than(2.21±0.21)L,(1.64±0.42)L and(54.02±6.68)%before treatment;the levels of FVC,FEV1 and FEV1/FVC of the conventional group were(2.36±0.35)L,(2.32±0.46)L and(74.31±6.18)%,which were better than(2.18±0.25)L,(1.66±0.33)L and(54.18±5.92)%before treatment;the levels of FVC,FEV1 and FEV1/FVC of the experimental group were better than those of the conventional group;all the difference was statistically significant(P<0.05).After treatment,the PaO_(2)(71.45±4.95)mm Hg(1 mm Hg=0.133 kPa)of the experimental group were higher than(51.02±6.38)mm Hg before treatment,and PaCO_(2)(45.19±6.18)mm Hg was lower than(68.95±8.52)mm Hg before trea
作者
王景
徐颖
段立鸣
WANG Jing;XU Ying;DUAN Li-ming(988 Hospital of the Joint Logistics Support Force of the People’s Liberation Army,Zhengzhou 450000,China)
出处
《中国现代药物应用》
2021年第16期4-7,共4页
Chinese Journal of Modern Drug Application
关键词
慢性阻塞性肺疾病
急性加重期
糖皮质激素
特布他林
肺功能
血气分析
Chronic obstructive pulmonary disease
Acute exacerbation
Glucocorticoid
Terbutaline
Lung function
Blood gas analysis
